Clinical effect of microecological modulator on rotavirus enteritis in children

doi:10.3877/cma.j.issn.2095-2015.2023.04.012

Abstract

Abstract:

Objective

To investigate the effect of Bifidobacterium Triple Viable Powder(Peifeikang)combined with compound Lactobacillus acidophilus tablets in the adjuvant treatment of rotavirus enteritis in children.

Methods

A total of 120 children with rotavirus enteritis treated in Guangde People′s Hospital from August 2020 to September 2022 were included and randomly divided into control group, Peifeikang group and combined bacteria group according to random number table method, with 40 cases in each group.The control group was given conventional rehydration treatment, the Peifeikang group was given Peifeikang preparation on the basis of conventional treatment, and the combined bacteria group was given probiotic preparations such as Peifeikang and compound Lactobacillus acidophilus tablets on the basis of conventional treatment.After 1-5 days of treatment, the clinical therapeutic effect, the changes of intestinal probiotics and pathogenic bacteria, intestinal permeability function and serum inflammatory factors were compared among the three groups.

Results

After treatment, the total effective rate of the combined bacteria group was significantly higher than that of the Peifeikang group and the control group(P<0.05). The disappearance time of clinical symptoms(diarrhea, abdominal pain, vomiting and dehydration)in the combined bacteria group was significantly earlier than that in the control group and the Pefikang group.Among the intestinal flora detected, Bifidobacterium intestinalis, Lactobacillus acidophilus and Enterococcus faecalis were increased in the three groups, and the increased proportion in the combined bacteria group was higher than that in the Peifeikang group and the control group(P<0.05). Enteric Escherichia coli and Perfringens were decreased in all three groups, and the reduction degree of the combined bacteria group was higher than that of the Peifeikang group and the control group(P<0.05). The decrease of serum D-lactic acid, DAO, ET and inflammatory factors(TNF-α, IL-1β, IL-6 and IL-17)levels in the combined bacteria group was higher than that in the Peifeikang group and the control group(P<0.05).

Conclusion

On the basis of conventional treatment, combination of Peifeikang and compound Lactobacillus acidophilus tablets can improve the therapeutic effect of rotavirus in children.

Key words: Rotavirus enteritis, Children, Live combined Bifidobacterium, Lactobacillus and Enterococcus powder, Compound Lactobacillus acidophilus tablets, Curative effect

Xianhong Lu, Shilu Qian, Min Zhou. Clinical effect of microecological modulator on rotavirus enteritis in children[J]. Chinese Journal of Digestion and Medical Imageology(Electronic Edition), 2023, 13(04): 245-249.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhxhbyyxzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2095-2015.2023.04.012

https://zhxhbyyxzz.cma-cmc.com.cn/EN/Y2023/V13/I04/245

Figures/Tables 6

References 20

1	Posovszky C，Buderus S，Classen M，et al.Acute Infectious Gastroenteritis in Infancy and Childhood[J]. Dtsch Arztebl Int，2020，117(37)：615-624.
2	Bányai K，Estes MK，Martella V，et al.Viral gastroenteritis[J]. Lancet，2018，392(10142)：175-186.
3	Amimo JO，Raev SA，Chepngeno J，et al.Rotavirus Interactions With Host Intestinal Epithelial Cells[J]. Front Immunol，2021，12：793841.
4	Roeger C，Khalil IA，Rao PC，et al.Rotavirus Vaccination and the Global Burden of Rotavirus Diarrhea Among Children Younger Than 5 Years[J]. JAMA Pediatr，2018，172(10)：958-965.
5	杨军，唐磊，乔振国．复方嗜酸乳杆菌联合标准四联疗法治疗幽门螺杆菌阳性消化性溃疡的临床研究[J]．中国医学创新，2023，20(14)：55-58.
6	中华医学会儿科学分会消化学组，中华医学会儿科学分会感染学组，《中华儿科杂志》编辑委员会．儿童腹泻病诊断治疗原则的专家共识[J]．中华儿科杂志，2009，47(8)：634-636.
7	王永艳．布拉酵母菌对轮状病毒肠炎患儿肠道菌群及免疫功能影响的前瞻性研究[J]．吉林医学，2023，44(4)：1042-1045.
8	Wu Y，Tu X，Liang X，et al.Gegen huangqin huanglian decoction for children rotavirus enteritis：A protocol for systematic review and meta-analysis[J]. Medicine(Baltimore)，2020，99(49)：e23376.
9	Ruff WE，Greiling TM，Kriegel MA.Host-microbiota interactions in immune-mediated diseases[J]. Nat Rev Microbiol，2020，18(9)：521-538.
10	El-Sayed A，Aleya L，Kamel M．Microbiota′s role in health and diseases[J]. Environ Sci Pollut Res Int，2021，28(28)：36967-36983.
11	Cai Y，Wang X，Li C，et al.Probiotics combined with zinc and selenium preparation in the treatment of child rotavirus enteritis[J]. Am J Transl Res，2022，14(2)：1043-1050.
12	Hu Y，Gui L，Chang J，et al.The incidence of infants with rotavirus enteritis combined with lactose intolerance[J]. Pak J Pharm Sci，2016，29(1 Suppl)：321-323.
13	Qiu CY，Guo ZX，Zhang GH，et al.Study on the effectiveness and safety of Xingpi Yanger granule combined with Saccharomyces boulardii for rotavirus enteritis in children：A protocol for systematic review and meta-analysis[J]. Medicine(Baltimore)，2021，100(16)：e25593.
14	徐春芳．双歧杆菌联合醒脾养儿颗粒辅助治疗小儿轮状病毒肠炎的效果[J]．实用临床医学，2023，24(2)：55-57，66.
15	李世兴．小儿泻速停颗粒联合复方嗜酸乳杆菌片治疗小儿轮状病毒肠炎的疗效分析[J]．北方药学，2022，19(1)：34-37.
16	董现立，王光明，赵变宇，等．双歧杆菌四联活菌联合肠炎宁治疗轮状病毒肠炎伴心肌损伤疗效观察[J]．实用中医药杂志，2022，38(11)：1932-1934.
17	王亚端，谭双羽，郑清梅，等．轮状病毒感染机制研究进展[J]．中国临床药理学杂志，2019，35(9)：900-902，906.
18	何丽，周骥，何元清，等．奥替溴铵对肠易激综合征患者肠道微生态和肠道屏障功能的影响[J]．实用医院临床杂志，2018，15(1)：115-118.
19	Liu P，Zou R，Zhao J，et al.Changes in humoral immunity，myocardial damage，trace elements，and inflammatory factor levels in children with rotavirus enteritis[J]. Am J Transl Res，2022，14(1)：452-459.
20	Dong H，Qu S，Chen X，et al.Changes in the cytokine expression of peripheral Treg and Th17 cells in children with rotavirus enteritis[J]. Exp Ther Med，2015，10(2)：679-682.

组别	男[例(%)]	女[例(%)]	年龄(岁)	病程(d)	白细胞计数(10⁹/L)	C反应蛋白(mg/L)	白蛋白(g/L)	血小板(10⁹/L)	红细胞(10¹²/L)
对照组	25(62.5)	15(37.5)	3.06±2.65	3.60±1.28	3.75±0.68	10.31±2.78	36.15±1.54	189.00±20.36	4.21±0.87
培菲康组	25(62.5)	15(37.5)	2.71±1.71	3.35±0.98	3.47±0.79	9.82±4.75	34.94±2.14	195.00±23.24	4.47±1.04
联合菌组	25(62.5)	15(37.5)	2.75±2.32	2.85±0.86	3.86±0.34	10.24±3.86	35.42±1.78	198.00±24.24	4.57±1.14
t/χ²	<0.000	<0.000	0.721	0.624	0.586	0.784	1.021	1.042	0.845
P	1.000	1.000	0.501	0.714	0.495	0.524	0.564	0.425	0.726

组别	男[例(%)]	女[例(%)]	年龄(岁)	病程(d)	白细胞计数(10⁹/L)	C反应蛋白(mg/L)	白蛋白(g/L)	血小板(10⁹/L)	红细胞(10¹²/L)
对照组	25(62.5)	15(37.5)	3.06±2.65	3.60±1.28	3.75±0.68	10.31±2.78	36.15±1.54	189.00±20.36	4.21±0.87
培菲康组	25(62.5)	15(37.5)	2.71±1.71	3.35±0.98	3.47±0.79	9.82±4.75	34.94±2.14	195.00±23.24	4.47±1.04
联合菌组	25(62.5)	15(37.5)	2.75±2.32	2.85±0.86	3.86±0.34	10.24±3.86	35.42±1.78	198.00±24.24	4.57±1.14
t/χ²	<0.000	<0.000	0.721	0.624	0.586	0.784	1.021	1.042	0.845
P	1.000	1.000	0.501	0.714	0.495	0.524	0.564	0.425	0.726

组别	例数	显效	有效	无效	总有效
对照组	40	16(40.0)	15(37.5)	9(22.5)	31(77.5)
培菲康组	40	22(55.0)^*	13(32.5)	5(12.5)^*	35(87.5)^*
联合菌组	40	26(65.0)^#	13(32.5)	1(2.5)^#	39(97.5)^#
χ²		4.980	0.296	7.314	7.314
P		0.026	0.862	0.026	0.026

组别	例数	显效	有效	无效	总有效
对照组	40	16(40.0)	15(37.5)	9(22.5)	31(77.5)
培菲康组	40	22(55.0)^*	13(32.5)	5(12.5)^*	35(87.5)^*
联合菌组	40	26(65.0)^#	13(32.5)	1(2.5)^#	39(97.5)^#
χ²		4.980	0.296	7.314	7.314
P		0.026	0.862	0.026	0.026

组别	例数		双歧杆菌	嗜酸乳杆菌	粪肠球菌	大肠杆菌	产气荚膜杆菌	葡萄球菌
对照组	40	治疗前	7.23±0.41	6.34±0.27	7.35±0.39	9.14±0.42	8.87±0.25	6.47±0.13
		治疗后	7.45±0.52^*	6.84±0.46^*	7.68±0.27^*	8.84±0.36^*	8.34±0.21^*	6.52±0.31
培菲康组	40	治疗前	7.16±0.31	6.01±0.32	7.32±0.34	9.25±0.38	8.96±0.28	6.68±0.24
		治疗后	7.84±0.54^*#	6.79±0.48^*	8.14±0.25^*#	8.64±0.32^*#	8.02±0.18^*#	7.03±0.21
联合菌组	40	治疗前	7.18±0.35	5.97±0.42	7.42±0.16	9.35±0.47	8.94±0.25	7.01±0.29
		治疗后	8.24±0.62^*#&	7.43±0.58^*#&	8.54±0.27^*#&	8.42±0.28^*#&	7.78±0.17^*#&	6.91±0.18
t			2.142	3.524	3.124	4.526	5.264	3.241
P			0.031	0.024	0.028	0.012	0.009	0.028

Please choose a citation manager

Content to export